Progression Free Survival and Predictor of Recurrence in DLBCL patients with Negative Interim 18FDG PET/CT Using Standardized Imaging and Reporting Protocols

Zaman, Maseeh uz; Fatima, Nosheen; Zaman, Areeba; Zaman, Unaiza; Zaman, Sidra; Tahseen, Rabia

doi:10.31557/apjcp.2020.21.8.2343

Cited by 8 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A mean effective dose of 0.013 mSv/MBq was measured, which is similar to the routinely used glucose analogue [ 18 F]FDG [ 13 , 14 ]. However, new generations of PET/CT imaging scanners and recent efforts have indicated that a lower [ 18 F]FDG dose is preferable [ 15 , 16 ], and thus the [ 18 F]Me4FDG dose can likely be reduced as well. Moreover, from the findings of the study, it is clear that [ 18 F]Me4FDG was very well tolerated by the volunteers, as we did not detect any significant changes in the measured vital and laboratory parameters before and one hour after the intravenous injection of this tracer.…”

Section: Discussionmentioning

confidence: 99%

In vivo assessment of safety, biodistribution, and radiation dosimetry of the [18F]Me4FDG PET-radiotracer in adults

Geist,

Ramirez,

Binder

et al. 2024

EJNMMI Res

View full text Add to dashboard Cite

Background Approaches targeting the sodium-glucose cotransporter (SGLT) could represent a promising future therapeutic strategy for numerous oncological and metabolic diseases. In this study, we evaluated the safety, biodistribution and radiation dosimetry of the glucose analogue positron emission tomography (PET) agent [18F] labeled alpha-methyl-4-deoxy-4-[18F]fluoro-D-glucopyranoside ([18F]Me4FDG) with high sodium-glucose cotransporter and low glucose transporter (GLUT) affinity. For this purpose, five healthy volunteers (1 man, 4 women) underwent multiple whole-body PET/computed tomography (CT) examinations starting with injection and up to 4 h after injection of averaged (2.4 ± 0.1) MBq/kg (range: 2.3–2.5 MBq/kg) administered activity. The PET/CT scans were conducted in 5 separate sessions, blood pressure and temperature were measured, and blood and urine samples were collected before the scans and one hour after injection to assess toxicity. Measurements of [18F]Me4FDG radioactivity in organs of interest were determined from the PET/CT scans at 5 time points. Internal dosimetry was performed on voxel level using a fast Monte Carlo approach. Results All studied volunteers could well tolerate the [18F]Me4FDG and no adverse event was reported. The calculated effective dose was (0.013 ± 0.003) mSv/MBq. The organs with the highest absorbed dose were the kidneys with 0.05 mSv/MBq per kidney. The brain showed almost no uptake. After 60 min, (12 ± 15) % of the administered dose was excreted into the bladder. Conclusion Featuring an effective dose of only 0.013 ± 0.003 mSv/MBq and no occurrence of side effects, the glucose analogue [18F]Me4FDG seems to be a safe radio-tracer with a favorable biodistribution for PET imaging and also within several consecutive scans. Trial registration number NCT03557138, Registered 22 February 2017, https://ichgcp.net/clinical-trials-registry/NCT03557138.

show abstract

Section: Discussionmentioning

confidence: 99%

In vivo assessment of safety, biodistribution, and radiation dosimetry of the [18F]Me4FDG PET-radiotracer in adults

Geist,

Ramirez,

Binder

et al. 2024

EJNMMI Res

View full text Add to dashboard Cite

show abstract

“…Thus, some urea-based PSMA ligands have been developed. These molecules display favorable binding affinity and stability with very efficient internalization into the cells [46][47][48] . The first urea-based compound to target PSMA in the brain was designed by Kozikowski et al 49 .…”

Section: Radiolabeled Psmamentioning

confidence: 99%

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer

Ritawidya¹,

Wongso²,

Effendi³

et al. 2023

Adv Pharm Bull

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several promising PSMA inhibitors from a variety of molecular scaffolds (e.g., phosphorous-, thiol-, and urea-based molecules) have been developed. In addition, PSMA inhibitors bearing macrocyclic chelators have attracted interest due to their favorable pharmacokinetic properties. Recently, conjugating a small PSMA molecule inhibitor-bearing 1,4,7,10-N,N,N’’,N’’’-1,4,7,10-tetraacetic acid (DOTA) chelator, as exemplified by [177Lu]Lu-DOTA-PSMA-617 could serve as a molecular imaging probe and targeted radioligand therapy of metastatic-castration resistant prostate cancer (mCRPC). Hence, studies related to mCRPC have drawn global attention. In this review, the recent development of PSMA ligand-617-labeled with 177Lu for the management of mCRPC is presented. Its molecular mechanism of action, safety, efficacy, and future direction are also described.

show abstract

“…Advanced image reconstruction methods 13–15 and improved detectors have contributed to PET/CT images of much higher spatial resolution and signal‐to‐noise ratio even at substantially lower injected radiotracer dosages. In addition, new CT hardware and software has been proposed to minimize radiation exposure due to the CT component 1,16–18 …”

Section: Introductionmentioning

confidence: 99%

“…In addition, new CT hardware and software has been proposed to minimize radiation exposure due to the CT component. 1,[16][17][18] Previous studies reported that CT contributes to over 50% of the estimated average radiation exposure in 18 F-fluorodeoxyglucose ([ 18 F]FDG) PET/CT examinations-depending on the application. 16,17,19 In South Korea, a nationwide survey was conducted involving all institutions operating PET/CT scanners to evaluate the patient's effective dose for different diagnostic PET/CT procedures performed with various PET tracers.…”

Section: Introductionmentioning

confidence: 99%

“…The CT dose depends on many parameters, including tube current (mA), and tube current modulation (CT Automatic Exposure Control with the trade name of CARE Dose4D in Siemens scanners), tube voltage (kVp), and kV modulation (with the trade name of CARE kV in Siemens scanners which is an automated function that adapts the tube voltage fitting to the individual patient, and the clinical task), gantry rotation speed/exposure time (s), pitch factor, scan length (field of view), collimation, slice thickness, and patient characteristics. 5,6,18 However, changing these parameters may affect contrast and resolution and introduces noise and artifacts. 27 Therefore, in parallel with developing CT dose optimization methods, some studies focus on improving the image quality of low dose CT scans.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ultra‐low dose CT scanning for PET/CT

Mostafapour,

Greuter,

van Snick

et al. 2023

Medical Physics

View full text Add to dashboard Cite

BackgroundThe use of computed tomography (CT) for attenuation correction (AC) in whole‐body PET/CT can result in a significant contribution to radiation exposure. This can become a limiting factor for reducing considerably the overall radiation exposure of the patient when using the new long axial field of view (LAFOV) PET scanners. However, recent CT technology have introduced features such as the tin (Sn) filter, which can substantially reduce the CT radiation dose.PurposeThe purpose of this study was to investigate the ultra‐low dose CT for attenuation correction using the Sn filter together with other dose reduction options such as tube current (mAs) reduction. We explore the impact of dose reduction in the context of AC‐CT and how it affects PET image quality.MethodsThe study evaluated a range of ultra‐low dose CT protocols using five physical phantoms that represented a broad collection of tissue electron densities. A long axial field of view (LAFOV) PET/CT scanner was used to scan all phantoms, applying various CT dose reduction parameters such as reducing tube current (mAs), increasing the pitch value, and applying the Sn filter. The effective dose resulting from the CT scans was determined using the CTDIVol reported by the scanner. Several voxel‐based and volumes of interest (VOI)‐based comparisons were performed to compare the ultra‐low dose CT images, the generated attenuation maps, and corresponding PET images against those images acquired with the standard low dose CT protocol. Finally, two patient datasets were acquired using one of the suggested ultra‐low dose CT settings.ResultsBy incorporating the Sn filter and adjusting mAs to the lowest available value, the radiation dose in CT images of PBU‐60 phantom was significantly reduced; resulting in an effective dose of nearly 2% compared to the routine low dose CT protocols currently in clinical use. The assessment of PET images using VOI and voxel‐based comparisons indicated relative differences (RD%) of under 6% for mean activity concentration (AC) in the torso phantom and patient dataset and under 8% for a source point in the CIRS phantom. The maximum RD% value of AC was 14% for the point source in the CIRS phantom. Increasing the tube current from 6 mAs to 30 mAs in patients with high BMI, or with arms down, can suppress the photon starvation artifact, whilst still preserving a dose reduction of 90%.ConclusionsIntroducing a Sn filter in CT imaging lowers radiation dose by more than 90%. This reduction has minimal effect on PET image quantification at least for patients without Body Mass Index (BMI) higher than 30. Notably, this study results need validation using a larger clinical PET/CT dataset in the future, including patients with higher BMI.

show abstract

Progression Free Survival and Predictor of Recurrence in DLBCL patients with Negative Interim 18FDG PET/CT Using Standardized Imaging and Reporting Protocols

Cited by 8 publications

References 30 publications

In vivo assessment of safety, biodistribution, and radiation dosimetry of the [18F]Me4FDG PET-radiotracer in adults

In vivo assessment of safety, biodistribution, and radiation dosimetry of the [18F]Me4FDG PET-radiotracer in adults

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer

Ultra‐low dose CT scanning for PET/CT

Contact Info

Product

Resources

About